Should You Get a Second Opinion on Cancer?

Research-informed explainer — last updated 2026-04-11

Yes, get a second opinion. This applies to almost every cancer diagnosis, and it applies before you start treatment. Most oncologists expect patients to seek one and will not be offended. For complex cancers, ambiguous pathology, or any cancer where molecular testing could change the treatment plan, a second opinion at a comprehensive cancer center is not optional — it is standard of care.

This article draws on peer-reviewed research from three oncologists in the Convene directory. Their published work spans the landmark discoveries in EGFR mutation testing, patient-reported outcomes in oncology, and the integration of specialist palliative care into cancer treatment — each a domain where access to specialist-level care changed what patients received and how long they lived.

Why a second opinion can change your treatment

A second opinion is not about doubting your doctor. It is about making sure the diagnosis is right, the molecular testing is complete, and you have access to the most current treatment options.

Consider lung cancer. In 2004, researchers including Bruce Johnson at Dana-Farber Cancer Institute published a landmark paper in Science demonstrating that EGFR mutations in lung tumors predicted dramatic responses to gefitinib, an oral targeted therapy [1]. A companion paper led by Mark Kris at Memorial Sloan Kettering found that these EGFR mutations were especially common in never-smokers — a patient population many community oncologists historically did not test, because they assumed those patients did not fit the typical lung cancer profile [4].

Before EGFR testing became routine at academic cancer centers, patients without access to that testing received cisplatin-based chemotherapy when targeted oral therapy would have worked far better. The difference was not marginal. EGFR-mutant tumors that respond to targeted therapy have response rates upward of 70%; responses to standard chemotherapy in the same population were a fraction of that. A patient in 2003 or 2004 who sought a second opinion at Dana-Farber or MSK was far more likely to receive EGFR testing and targeted therapy — a difference measured in years of survival, not months.

This is not ancient history. The underlying principle still applies. Molecular profiling has expanded from EGFR to dozens of actionable mutations across multiple cancer types. A community oncologist who does not order comprehensive genomic testing on your tumor may not be doing anything wrong by the standards of their practice — but a specialist at a comprehensive cancer center may order testing that changes your treatment plan entirely.

When a second opinion is especially important

Some clinical situations make a second opinion more urgent than others:

Rare or unusual cancer type. If you have been diagnosed with a cancer that your oncologist does not see frequently, a specialist with disease-specific expertise will have managed many more similar cases and may be aware of options your treating physician has not considered.

Ambiguous pathology. Some biopsy results are described as atypical, borderline, or difficult to classify. Pathology interpretation at a high-volume cancer center — where pathologists see hundreds of similar samples — is often more reliable than a community hospital pathology department. Misclassifying a tumor type can lead to entirely the wrong treatment.

No molecular or genomic testing has been performed. If your oncologist has not mentioned comprehensive molecular profiling or next-generation sequencing (NGS) of the tumor, ask. For many cancer types — lung, breast, colon, melanoma, ovarian, and others — the presence or absence of specific mutations determines whether targeted therapy or immunotherapy will work. Chemotherapy is sometimes recommended not because it is the best option but because the testing to identify a better option was not done.

A major irreversible surgery is being recommended. Before agreeing to any surgery that removes an organ, affects function permanently, or carries significant long-term consequences, a second surgical opinion is prudent. The operative approach, the extent of resection, and even the decision of whether surgery is necessary at all can differ substantially between centers.

You want to know if a clinical trial is available. Academic cancer centers run far more clinical trials than community hospitals. The only way to know whether a trial you might qualify for exists is to ask someone who has access to a broad trial portfolio. Your community oncologist may not know what is available at centers they are not affiliated with.

You are not responding to first-line treatment. If your cancer is progressing despite treatment, a second opinion can surface resistance mechanisms and alternative options that a generalist may not be tracking. A 2007 paper in Science from Johnson and colleagues identified MET amplification as a resistance mechanism in patients whose tumors initially responded to EGFR inhibitors and then progressed — a level of biological complexity that requires specialist expertise to navigate [2].

The recommended treatment has serious long-term side effects. Certain surgeries, radiation regimens, and chemotherapy protocols carry risks that persist for years. A specialist may know of equivalent or superior options with a better long-term toxicity profile.

What comprehensive cancer centers offer that community oncologists may not

Not all oncology practices have the same resources. Comprehensive cancer centers — designated by the National Cancer Institute or affiliated with academic medical schools — typically offer several things that community hospitals do not:

Multidisciplinary tumor boards. At major centers, your case is reviewed by a panel that includes a medical oncologist, radiation oncologist, surgeon, radiologist, and pathologist simultaneously. The treatment plan emerges from a consensus of multiple specialists, not a single physician.

On-site molecular pathology. High-volume centers have pathology departments that process thousands of oncology cases per year. They are more likely to correctly classify unusual tumor types and to offer the most current genomic testing panels.

Disease subspecialists. A thoracic oncologist who has managed a thousand lung cancer cases is different from a general oncologist who sees lung cancer among dozens of other tumor types. For less common cancers, the difference in experience can be significant.

Access to clinical trials. Academic cancer centers are where most phase I and II trials run. Early-phase trials sometimes offer access to drugs that are not yet available commercially and that may be the best option for your specific tumor profile.

Integration of specialist palliative care. Research by Jennifer Temel at Massachusetts General Hospital demonstrated in a landmark 2010 trial published in the New England Journal of Medicine that patients with metastatic non-small-cell lung cancer who received early palliative care alongside standard oncology lived longer than those who received standard oncology alone — 11.6 months versus 8.9 months (p=0.02) — despite the palliative care group receiving less aggressive treatment at the end of life [7]. A subsequent randomized trial confirmed the benefit extended to GI cancers as well [9]. This work led to updated ASCO guidelines recommending early palliative care integration for patients with advanced cancer [8]. Comprehensive cancer centers are more likely to have this infrastructure in place from the start of treatment.

What to bring to a second opinion

The quality of a second opinion depends on the quality of the information the reviewing oncologist has access to. Bring the following:

• The pathology report — and request that your actual tissue slides (or a tissue block for re-cutting) be sent to the second-opinion center's pathology department, not just the written summary
• All imaging on CD or electronic transfer, including the original CT, PET, or MRI scans, not just the radiology reports
• A list of current medications and any relevant medical history
• Any operative reports if surgery has already been performed
• Results of any molecular or genetic testing that has been ordered

The most important question to ask before the visit: has comprehensive molecular profiling (NGS) been done on my tumor? If not, ask whether it should be done before or at the time of the second opinion consultation.

Will getting a second opinion delay my treatment?

For most cancers, no. The time between diagnosis and the start of treatment is often used for additional staging workup, insurance authorization, and scheduling. Requesting a second opinion review typically takes one to two weeks. In most cases, the time is better spent getting complete information than beginning treatment before the workup is finished.

There are exceptions. Certain highly aggressive cancers — some leukemias, rapidly growing lymphomas, some stage IV solid tumors with immediately life-threatening complications — may need treatment to begin quickly. Your treating oncologist can tell you if urgency is a genuine factor. Even then, many academic centers have mechanisms to review cases rapidly for patients in time-sensitive situations.

If you are concerned about timing, ask your oncologist directly: "Is there a clinical reason we need to start treatment before I get a second opinion?" That is a fair question, and the answer should inform how quickly you move.

Questions to bring to a second opinion

• Has my tumor been tested for all currently actionable mutations and biomarkers? Which testing platform was used?
• Does the pathology interpretation at this center match the diagnosis I received?
• Are there clinical trials I qualify for that I should consider before or instead of standard treatment?
• Is the recommended treatment — whether surgery, chemotherapy, targeted therapy, or immunotherapy — the standard of care for my specific tumor type and stage at this center?
• Are there differences in the surgical approach, radiation technique, or drug regimen that this center would recommend versus what I was told?
• What are the long-term effects of the recommended treatment, and are there alternatives with a different toxicity profile?
• Will I have access to specialist palliative care support alongside my treatment?

The bottom line

Getting a second opinion after a cancer diagnosis is not an act of distrust — it is a standard part of good cancer care. Research that changed oncology practice did not reach community hospitals instantaneously. The discovery that EGFR mutations predict treatment response [1], the finding that never-smoker lung cancer is particularly likely to carry actionable mutations [4], and the demonstration that early specialist palliative care improves survival [7] — all of these findings took time to propagate from academic centers into widespread practice. The gap between what is done at the most specialized centers and what is done everywhere else is real, and it affects outcomes.

Most oncologists will help facilitate a second opinion. They will send records, coordinate pathology slide transfers, and refer you to a colleague. If your oncologist discourages you from seeking one, that itself is a reason to seek one.

You have time. Get the complete picture before you start treatment.